<DOC>
	<DOCNO>NCT00101062</DOCNO>
	<brief_summary>RATIONALE : Estrogen cause growth breast cancer cell . Hormone therapy use letrozole may fight breast cancer lower amount estrogen body make . Celecoxib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Giving letrozole celecoxib may kill tumor cell . PURPOSE : This phase II trial study well letrozole celecoxib work treat postmenopausal woman locally advance metastatic breast cancer .</brief_summary>
	<brief_title>Letrozole Celecoxib Treating Postmenopausal Women With Locally Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate postmenopausal woman hormone receptor-positive locally advanced metastatic adenocarcinoma breast treat letrozole celecoxib first-line therapy . Secondary - Determine time disease progression overall survival patient treat regimen . - Determine toxicity regimen patient . - Compare cyclooxygenase activity blood tumor cell patient treatment regimen . - Determine effect regimen aromatase activity , tumor proliferation , angiogenesis tumor sample patient . OUTLINE : This multicenter study . Patients receive oral letrozole daily oral celecoxib twice daily day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients follow survival . PROJECTED ACCRUAL : A total 45-72 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma breast Locally advance metastatic disease Measurable disease No bone disease No history brain metastasis unless control radiotherapy surgical resection ≥ 6 month study entry Hormone receptor status : Estrogen receptor OR progesterone receptorpositive PATIENT CHARACTERISTICS : Age 18 Sex Female Menopausal status Postmenopausal , define 1 following : Prior bilateral oophorectomy Prior bilateral ovarian irradiation No spontaneous menstrual bleeding within past 12 month Age 55 AND prior hysterectomy without oophorectomy Age 54 AND prior hysterectomy without oophorectomy ( status ovary unknown ) AND document folliclestimulating hormone level postmenopausal range Performance status ECOG 02 Life expectancy At least 3 month Hematopoietic Granulocyte count ≥ 1,000/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN Renal Creatinine ≤ 1.5 time ULN Other No prior allergic reaction attribute compound similar chemical biologic composition study drug No prior allergic reaction sulfonamides No active peptic ulcer disease No active infection No medical condition would preclude study participation Able swallow oral medication PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy metastatic recurrent disease Endocrine therapy No prior endocrine therapy metastatic disease Prior adjuvant tamoxifen allow No prior aromatase inhibitor No prior hormonal therapy recurrent disease No concurrent hormonal therapy Radiotherapy See Disease Characteristics See Menopausal status No concurrent radiotherapy Surgery See Disease Characteristics See Menopausal status Other No concurrent fluconazole lithium No concurrent aspirin , nonsteroidal antiinflammatory drug , cyclooxygenase2 inhibitor Concurrent chronic cardioprotective lowdose aspirin allow No concurrent investigational agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>